COMMENTARY: Review: Trials of injectable pneumococcal vaccines do not show effectiveness in chronic obstructive pulmonary disease

McGeer, Allison
March 2007
ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p36
Academic Journal
The article presents the author's comment on a research study focusing on the role of injectable vaccines in the prevention of pneumococcal infection in patients with chronic obstructive pulmonary disease. The author says that although preventing these infections is clearly desirable, the study did not show any benefit from pneumococcal polysaccharide vaccines. He opines that like many other negative studies, the results of this study also are of little use in decision making.


Related Articles

  • General considerations.  // WHO Technical Report Series;2004, Issue 927, p66 

    The article focuses on polysaccharide vaccines for infections caused by Streptococcus pneumoniae, which are responsible for substantial morbidity and mortality, commonly on children and the elderly. Pneumociccus are classified based on chemical and serological distinct capsular polysaccharides....

  • Update: Pneumococcal Polysaccharide Vaccine Usage--United States.  // Annals of Internal Medicine;Sep84, Vol. 101 Issue 3, p348 

    Discusses the revised recommendations of the Immunization Practices Advisory Committee on pneumococcal polysaccharide vaccine. Effectiveness of pneumococcal polysaccharide vaccines; Methods of estimating the efficacy of pneumococcal vaccine; Strategies for vaccine delivery.

  • Comparison of Pneumococcal Conjugate Polysaccharide and Free Polysaccharide Vaccines in Elderly Adults: Conjugate Vaccine Elicits Improved Antibacterial Immune Responses and Immunological Memory. Roux, Andrés de; Schmöele-Thoma, B.; Siber, G. R.; Hackell, J. G.; Kuhnke, A.; Ahlers, N.; Baker, S. A.; Razmpour^6, A.; Emini, E. A.; Fernsten, P. D.; Gruber, W. C.; Lockhart^6, S.; Burkhardt, O.; Welte, T.; Lode, H. M. // Clinical Infectious Diseases;4/1/2008, Vol. 46 Issue 7, p1015 

    Background. High functional antibody responses, establishment of immunologic memory, and unambiguous efficacy in infants suggest that an initial dose of conjugated pneumococcal polysaccharide (PnC) vaccine may be of value in a comprehensive adult immunization strategy. Methods. We compared the...

  • PCV13 worth a shot in immunocompromised adults.  // PharmacoEconomics & Outcomes News;Nov2013, Issue 691, p8 

    The article reports on the main findings of a U.S. study which unveil that adding one dose of 13-valent pneumococcal conjugate vaccine (PCV13) to 23-valent pneumococcal polysaccharide vaccine (PPSB23) effectively reduces diseases burden and costs in adults with selected immunocompromised conditions.

  • Neumococo, Nuevas Actuales y Nuevas Vacunas. Reyes-Gómez, Ulises; Cruz-García, Leticia Gabriela; Arista-Viveros, Antonio; López-Cruz, Gerardo; Garzón-Sánchez, Ernesto; Colón-Cuesta, Francisco // Boletin Clinico Hospital Infantil del Estado de Sonora;2011, Vol. 28 Issue 1, p27 

    The Streptococcus pneumoniae or pneumococcus, causes serious infections in children ranging from pneumonia, sepsis and meningitis. Across the time, pneumococcal has shown increasing resistance to antimicrobials classics. One of the best strategies of prevention are the vaccines. Our country...

  • Annex 2: Recommendations for the production and control of pneumococcal conjugate vaccines.  // WHO Expert Committee on Biological Standardization;2005, p64 

    Annex 2 of the book "WHO Expert Committee on Biological Standardization: fifty-fourth report" is presented. It explores the collaborative studies which recommended the production and control of pneumococcal conjugate vaccines. It discusses the development of bacterial capsular polysaccharide...

  • The effect of age on the response to the pneumococcal polysaccharide vaccine. Hyunju Lee; Nahm, Moon H.; Kyung-Hyo Kim // BMC Infectious Diseases;2010, Vol. 10 Issue 1, p60 

    Background: Streptococcus pneumoniae is a leading cause of morbidity and mortality in the elderly. To prevent invasive pneumococcal diseases, the 23-valent pneumococcal polysaccharide vaccine (PPV) is recommended in subjects over 65 years of age. Although it has been reported to provide...

  • Efficacy of the Pneumococcal Conjugate Vaccine. Deresinski, Stan // Clinical Infectious Diseases;8/15/2007, Vol. 45 Issue 4, pvi 

    The article reports on the efficacy of pneumococcal conjugate vaccine in reducing pneumonia admissions in the U.S. Since the 7-valent vaccine has been licensed in February 2000 in the U.S., its administration has been widely enforced. According to the data from the Nationwide Inpatient Sample,...

  • Vaccination against pneumococcus in West Africa: perspectives and prospects. Donkor, Eric S.; Dayie, Nicholas T. K. D.; Badoe, Ebenezer V. // International Journal of General Medicine;2013, Vol. 6, p757 

    Background: Pneumococcal vaccination has become obligatory due to the enormous burden of pneumococcal diseases. Quite recently, pneumococcal conjugate vaccines have been developed, and have been shown to be superior to the previous polyvalent polysaccharide vaccine of the organism. Pneumococcal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics